Gudaf Tsegay, the Ethiopian athlete and former two-time world champion, has been handed a four-month ban for a doping violation. The decision follows her admission of a prohibited substance found during an out-of-competition test conducted in December last year. Tsegay, who secured the women's 5,000m world title in 2022 and the 10,000m crown in 2023, also earned a bronze medal in the shorter distance at the Tokyo 2020 Olympics.
The substance identified in Tsegay's sample was a metabolite of Letrozole, which is classified as an aromatase inhibitor on the World Anti-Doping Agency (WADA) prohibited list. Letrozole is commonly used in the medical field to lower oestrogen levels, particularly in the treatment of breast cancer.
Upon being notified of the test results by the Athletics Integrity Unit (AIU) in late January, Tsegay promptly explained that she had been prescribed Letrozole to manage a diagnosed medical condition. She provided supporting medical documentation and evidence to substantiate her claim. In February, Tsegay submitted an application for a Therapeutic Use Exemption (TUE) to World Athletics. This application confirmed that her treatment adhered to WADA's international standard requirements for TUEs.
However, despite this, WADA ultimately rejected her request for a retroactive TUE, which would have granted an exemption for exceptional reasons. Subsequently, Tsegay entered into a case resolution agreement with both WADA and the AIU. An AIU statement clarified that a four-month ban was deemed 'appropriate' under regulations pertaining to cases where there is no fault or negligence on the part of the athlete.
The duration of the sanction was determined based on several factors, including Tsegay's degree of fault, her swift admission of the violation, and the acknowledgement that the presence of Letrozole met WADA's international standards for TUEs. Crucially, it was recognised that a TUE would have been granted had it been requested in advance. The period of ineligibility has been backdated to 1 June and is set to conclude on 30 September.
This case highlights the stringent regulations within international athletics regarding the use of prohibited substances, even when prescribed for legitimate medical conditions. Athletes are required to seek advanced therapeutic exemptions to avoid sanctions, underscoring the importance of adherence to anti-doping protocols.